Medicare Part D plans cover popular obesity drugs if they are used for an additional medically accepted purpose as approved by the FDA.

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and Drug Administration approval last month.

The cost to taxpayers could be enormous. Sales growth of Zepbound in the U.S. has been constrained by rules that bar Medicare, the government-funded insurance plan for people over 65, from paying ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

The 15 drugs selected for negotiation are prescribed to 5.3 million Medicare beneficiaries to treat conditions ranging from ...

Medicare won't seek to negotiate lower prices for Eli Lilly's popular diabetes drug Mounjaro and weight loss drug Zepbound because they haven't been on the market long enough to be eligible.

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Neither Medicare nor Medicaid covers weight loss medications like Zepbound. While Eli Lilly doesn’t offer specific pricing information for Zepbound, it has a savings program. With eligible ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

Medicare spent $14.4 billion on Ozempic and ... Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound are expected to become subject to negotiations in coming years. Also, the program faces a multitude ...